Angela Vasaturo, PhD; Julia Katerina Schwarze, MD
Associate Director Scientific Affairs, Ultivue; Dept of Medical Oncology, University Hospital Brussels
Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors
Length: 60 minutes
Relevant for
FixVUE, InSituPlex
Description In this exciting webinar co-hosted by GEN and Clinical OMICs, we explored the intratumoral administration of autologous, non-manipulated myeloid dendritic cells in combination with immune checkpoint inhibitors in patients with advanced solid tumors and in combination with the oncolytic virus talimogene laherparepvec (Imlygic®) in patients with advanced melanoma in phase I clinical trials. Additionally, we heard how on-treatment biopsies are analyzed for cellular changes with immunohistochemistry and multiplexed immunofluorescence, which could serve as a surrogate biomarker.
Meet the host
Angela Vasaturo is the Associate Director Scientific Affairs at Ultivue. Prior to joining Ultivue she was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Centre. She has a wealth of expertise in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.
Related Content
Improved Understanding of the Biology and Pathophysiology of the TME in PDAC Samples Revealed by Both InSituPlex and Imaging Mass Cytometry
Presented at AACR 2022
Tissue-based characterization of T cell exhaustion in inflammatory bowel disease and colorectal cancer using multiplex IHC
Fast and accurate spatial phenotyping and immuno-profiling using Ultivue UltiMapper kits and the ZEISS Axioscan 7 slide scanner
Ultivue
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Length: 46 minutes
Gene Expression Profiling, Digital Spatial Profiling and Multiplex Immunohistochemistry of the Tumor-Immune Microenvironment in HNSCC Tumors
Presented at AACR 2020
